Biopharming Regulations | GenomeWeb

Using genetic engineering in plants to create biopharmed drugs holds all sorts of promise for treating diseases, as the recent case of a drug which appears to have cured two Ebola patients has shown, but regulators may be holding this field back, argues Henry Miller in a Wall Street Journal op-ed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: diatom genetic diversity, microfluidic droplet method for single-cell screening, and more.

Scientific publishers are looking into whether artificial intelligence can help the peer-review process, Wired reports.

Researchers are using gene editing to develop more robust livestock and crops, AFP reports.

Researchers rally near the American Association for the Advancement of Science annual meeting in Boston.